Abcam, ab263245, Human LIMCH1 knockout HeLa cell lysate

Size: 1Kit
LIMCH1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 8 and 8 bp deletion in exon 8.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 8 and 8 bp deletion in exon 8.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LIMCH1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The LIM and Calponin Homology Domain 1 known as LIMCH1 is a protein with a mass of approximately 90 kDa. It functions mechanically by interacting with actin filaments influencing their organization and stability. LIMCH1 contains a LIM domain which provides a scaffold for protein-protein interactions and a calponin homology domain which binds actin. LIMCH1 is expressed in various tissues including skeletal muscle heart and brain indicating its involvement in multiple cellular functions.
Biological function summary
LIMCH1 modulates cytoskeletal dynamics and plays a role in cell shape and motility. It forms part of protein complexes that regulate the architecture of the actin cytoskeleton. These complexes involve other actin-binding proteins contributing to processes like cell adhesion and migration. LIMCH1 influences the remodeling of cytoskeletal structures critical for cellular responses to environmental changes and mechanical stress.
Pathways
Researchers identify LIMCH1 as a component in the RhoA signaling pathway which controls actin cytoskeleton dynamics. LIMCH1 interacts with proteins like Rho-associated protein kinase (ROCK) and myosin light chain kinase (MLCK) coordinating actomyosin contractility. Another significant pathway involving LIMCH1 is the regulation of focal adhesion where it associates with vinculin and talin contributing to the linkage between the plasma membrane and the cytoskeletal framework.
Abnormalities in LIMCH1 expression or function relate to conditions such as heart hypertrophy and certain types of cancer. In cardiac muscle cells disrupted LIMCH1 activity can lead to altered contractility linking it to heart disease. Furthermore in the context of cancer LIMCH1's modulation of cell migration and adhesion connects it to metastasis. Studies also find its interactions with proteins like p53 a well-known tumor suppressor as important in these disease processes.